Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group
- PMID: 10615932
- PMCID: PMC1420941
- DOI: 10.1097/00000658-199912000-00006
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group
Abstract
Objective: The survival benefit of adjuvant radiotherapy and 5-fluorouracil versus observation alone after surgery was investigated in patients with pancreatic head and periampullary cancers.
Summary background data: A previous study of adjuvant radiotherapy and chemotherapy in these cancers by the Gastrointestinal Tract Cancer Cooperative Group of EORTC has been followed by other studies with conflicting results.
Methods: Eligible patients with T1-2N0-1aM0 pancreatic head or T1-3N0-1aM0 periampullary cancer and histologically proven adenocarcinoma were randomized after resection.
Results: Between 1987 and 1995, 218 patients were randomized (108 patients in the observation group, 110 patients in the treatment group). Eleven patients were ineligible (five in the observation group and six in the treatment group). Baseline characteristics were comparable between the two groups. One hundred fourteen patients (55%) had pancreatic cancer (54 in the observation group and 60 in the treatment group). In the treatment arm, 21 patients (20%) received no treatment because of postoperative complications or patient refusal. In the treatment group, only minor toxicity was observed. The median duration of survival was 19.0 months for the observation group and 24.5 months in the treatment group (log-rank, p = 0.208). The 2-year survival estimates were 41% and 51 %, respectively. The results when stratifying for tumor location showed a 2-year survival rate of 26% in the observation group and 34% in the treatment group (log-rank, p = 0.099) in pancreatic head cancer; in periampullary cancer, the 2-year survival rate was 63% in the observation group and 67% in the treatment group (log-rank, p = 0.737). No reduction of locoregional recurrence rates was apparent in the groups.
Conclusions: Adjuvant radiotherapy in combination with 5-fluorouracil is safe and well tolerated. However, the benefit in this study was small; routine use of adjuvant chemoradiotherapy is not warranted as standard treatment in cancer of the head of the pancreas or periampullary region.
Figures
Comment in
-
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region.Ann Surg. 2000 Nov;232(5):726-7. doi: 10.1097/00000658-200011000-00027. Ann Surg. 2000. PMID: 11066156 Free PMC article. No abstract available.
-
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region.Ann Surg. 2000 Nov;232(5):727. doi: 10.1097/00000658-200011000-00028. Ann Surg. 2000. PMID: 11066157 Free PMC article. No abstract available.
-
On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer.Ann Surg. 2006 Aug;244(2):332-3; author reply 333. doi: 10.1097/01.sla.0000229980.81505.44. Ann Surg. 2006. PMID: 16858208 Free PMC article. No abstract available.
Similar articles
-
Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial.Ann Surg. 2008 Dec;248(6):1031-41. doi: 10.1097/SLA.0b013e318190c53e. Ann Surg. 2008. PMID: 19092348 Clinical Trial.
-
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region.Ann Surg. 2000 Nov;232(5):727. doi: 10.1097/00000658-200011000-00028. Ann Surg. 2000. PMID: 11066157 Free PMC article. No abstract available.
-
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region.Ann Surg. 2000 Nov;232(5):726-7. doi: 10.1097/00000658-200011000-00027. Ann Surg. 2000. PMID: 11066156 Free PMC article. No abstract available.
-
Adjuvant therapy in pancreatic cancer: a critical appraisal.Drugs. 2007;67(16):2293-310. doi: 10.2165/00003495-200767160-00001. Drugs. 2007. PMID: 17983252 Review.
-
Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium.Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):364-8. doi: 10.1016/j.ijrobp.2008.11.069. Int J Radiat Oncol Biol Phys. 2009. PMID: 19735864 Review.
Cited by
-
Circadian Genes as Therapeutic Targets in Pancreatic Cancer.Front Endocrinol (Lausanne). 2020 Sep 11;11:638. doi: 10.3389/fendo.2020.00638. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33042011 Free PMC article. Review.
-
Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question?Contemp Oncol (Pozn). 2016;20(2):102-8. doi: 10.5114/wo.2016.60066. Epub 2016 Jun 14. Contemp Oncol (Pozn). 2016. PMID: 27358587 Free PMC article. Review.
-
The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer.Expert Rev Anticancer Ther. 2012 Apr;12(4):469-80. doi: 10.1586/era.12.18. Expert Rev Anticancer Ther. 2012. PMID: 22500684 Free PMC article. Review.
-
Long-Term Outcomes and Prognostic Factors in Periampullary Carcinoma.J Gastrointest Cancer. 2017 Mar;48(1):13-19. doi: 10.1007/s12029-016-9863-z. J Gastrointest Cancer. 2017. PMID: 27484980
-
Early mortality risk score: identification of poor outcomes following upfront surgery for resectable pancreatic cancer.J Gastrointest Surg. 2012 Apr;16(4):753-61. doi: 10.1007/s11605-011-1811-4. Epub 2012 Feb 7. J Gastrointest Surg. 2012. PMID: 22311282 Free PMC article.
References
-
- Parker SL, Tony T, Bolden S, Wingo PA. Cancer Statistics, 1997. CA Cancer J Clin 1997; 47: 5–27. - PubMed
-
- Trede M. The surgical treatment of pancreatic carcinoma. Surgery 1985; 97: 28–35. - PubMed
-
- Klinkenbijl JHG, Jeekel J, Schmitz PIM, et al. Carcinoma of the pancreas and periampullary region: palliation versus cure. Br J Surg 1993; 80: 1575–1578. - PubMed
-
- Wanebo HJ, Vezeridis MP. Pancreatic carcinoma in perspective. A continuing challenge. Cancer 1996; 78 (3 Suppl): 580–591. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical